Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Epizyme Inc (EPZM), Portola Pharmaceuticals Inc (PTLA): Why Are These Two Recent IPOs So Promising To You?

Page 1 of 2
Epizyme Inc (NASDAQ:EPZM) and Portola Pharmaceuticals Inc (NASDAQ:PTLA), are two pharmaceutical companies that recently filed IPOs. As sub-$600 million companies they are relatively unknown and have received very little coverage to-date. However, both have very promising pipelines with the potential to produce large revenue for many years to come. As a result, let’s take a look and determine if the risk is worth the reward, and whether or not these two stocks would make nice additions to your portfolio.

Making strides in treating genetically defined cancers

Epizyme is a biopharmaceutical company that discovers, develops and plans to offer innovative personalized therapeutics for patients with genetically defined cancers. The company has set its sights on developing a drug for certain types of cancers, including hematological cancers and solid tumors. The best part is that not only does Epizyme Inc (NASDAQ:EPZM) want to treat cancer symptoms, but their goal is to find the underlying causes of certain types of cancer.

Provided with a strong support group with investors such as New Enterprise Associates, Kleiner Perkins Caufield & Byers, Bay City Capital and MPM Capital, these, as well as an affiliate of Celgene, are providing a hefty cash flow; as of March 31, 2013, Epizyme Inc (NASDAQ:EPZM) had $85 million in cash and cash equivalents.

Epizyme Inc (NASDAQ:EPZM) is only in Phase 1-2 trials.  If these trials, based on small molecule therapeutics, turn out to be successful, certain types of leukemia would be able to go into remission, thus making for a huge breakthrough in the medical field and providing a much needed optimistic disposition in the diagnostics of the dreaded disease. During the escalation phase of experimentation, one of the patients experienced a 90% reduction in circulating leukemic blast count in her blood by the fifth day of EPZ-5676 treatment.

Epizyme Inc (NASDAQ:EPZM) IPO’d at $15 per share on May 31, 2013. The equity nearly doubled in a matter of three days. Why? It could be that Epizyme has its funding in place–over $1 billion in fact–to continue its research and operations. Or, it could be its potential, as Epizyme’s approach could produce sales north of $1 billion, and might also result in an orphan designation. Thus, its $660 million market cap is not expensive, if in fact the data continues to impress. If it does, this could be a great investment for several years to come.

Diversified, late-stage company with loads of upside

Portola Pharmaceuticals Inc (NASDAQ:PTLA) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics in areas of thrombosis, hematologic disorders and inflammation for patients who currently have either very limited treatment, or no treatment options at all. Based out of South San Francisco, CA., Portola scheduled a $100 million IPO with a market capitalization of $469 million at a price range mid-point of $14, on Wednesday, May 22, 2013.

A clinical study, which is in Phase III, investigates the company’s oral, once a day lead product called Betrixaban, with comparison to an injection of enoxaparin in acute medically ill patients with restricted mobility and other risk factors. Based on the anticipation enrollment of 6,850 patients, Portola Pharmaceuticals Inc (NASDAQ:PTLA) expects its current Phase III study of Betrixaban, or APEX, to be completed by summer of 2015.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!